Skip to content

US · AKBA · BIOTECHNOLOGY

Akebia Therapeutics, Inc. (AKBA) intrinsic value and stock valuation

$0.39as of 2026-11-21 · Mkt cap 346.05M

Data updated · price as of 2026-11-21

IC valuationIntrinsic value, upside vs price and the fair-value band are available to Pro members.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

Akebia Therapeutics, Inc. DCF and intrinsic value

InvestorsCraft values AKBA with the Chepakovich two-stage DCF model. How the model works · Run your own DCF prefilled from AKBA’s statements →

Akebia Therapeutics, Inc. Graham Number

The Graham Number is not defined for negative earnings or book value. Guide · Calculator →

Healthcare · Biotechnology Cambridge, MA 02142 akebia.com

How the business is doing

Fiscal 2012–2025, USD

Revenue
$236.2M-4.3% 5y CAGRd
20122025
Net income
-$-5.34M
20122025
Free cash flow
$68M
20122025
Total equity
$32.6M-33.3% 5y CAGRd
20122025

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Peers

Same-industry companies, ranked by market cap

Peer comparison

The peer comparison table is shown only to users with a Pro subscription.

Financials

Statements by fiscal year

Fiscal 2012–2025, USD
20252024202320222021
Revenue$236.2M$160.2M$194.6M$292.5M$211.7M
Operating income$23.5M-$-50.47M-$-46.26M-$-80.78M-$-264.5M
Net income-$-5.34M-$-69.41M-$-51.92M-$-94.23M-$-282.02M
EPSd-$-20.77K-$-329.04K-$-276.95K-$-515.54K-$-1.7M
Operating cash flow$68M-$-40.66M-$-23.38M-$-73.15M-$-252.97M
Capital expenditure-$-290K-$-30K$0.00-$-110K-$-60K
Free cash flow$68M-$-40.69M-$-23.38M-$-73.27M-$-253.02M
Total assets$376.6M$220.7M$241.7M$356.1M$529.4M
Total debt$216.3M$188.7M$104.2M$99.8M$189.1M
Net debt$31.5M$136.9M$61.3M$9.32M$39.3M
Total equity$32.6M-$-49.19M-$-30.58M$5.23M$74M
Cash and short-term investments$184.8M$51.9M$42.9M$90.5M$149.8M
Income statement
20252024202320222021
Revenue$236.2M$160.2M$194.6M$292.5M$211.7M
Cost of revenue$39.5M$63.2M$74.2M$22.5M$81.5M
Gross profit$196.7M$97M$120.5M$270M$130.2M
Research and development expenses$62.4M$37.7M$63.1M$166M$147.9M
Selling, general and administrative expenses$107.5M$106.6M$100.2M$138.6M$174.1M
Other expenses$3.4M$3.28M$3.42M$46.2M$72.7M
Operating expenses$173.2M$147.5M$166.7M$350.8M$394.7M
Cost and expenses$212.7M$210.7M$240.9M$373.3M$476.2M
Interest income$0.00$0.00$0.00$0.00$0.00
Interest expense$24.2M$18.2M$6.03M$15.7M$19.9M
Depreciation and amortization$1.27M$37.5M$37.6M$37.7M$38M
Ebitda$21.7M-$-13.72M-$-8.27M$3.06M-$-189.91M
Operating income$23.5M-$-50.47M-$-46.26M-$-80.78M-$-264.5M
Total other income/expenses, net-$-27.22M-$-18.94M-$-5.67M-$-13.45M-$-17.52M
Income before tax-$-3.72M-$-69.41M-$-51.92M-$-94.23M-$-282.02M
Income tax expense$1.62M$0.00$0.00$0.00$0.00
Net income-$-5.34M-$-69.41M-$-51.92M-$-94.23M-$-282.02M
Weighted average shares outstanding$257.2M$211M$187.5M$182.8M$166M
Weighted average diluted shares outstanding$257.2M$211M$187.5M$182.8M$166M
Balance sheet
20252024202320222021
Cash and short-term investments$184.8M$51.9M$42.9M$90.5M$149.8M
Net receivables$47M$34.4M$39.3M$40.3M$51.6M
Inventory$15.6M$16.2M$15.7M$21.6M$36.6M
Total current assets$184.8M$113.8M$118.2M$185.2M$271.2M
Property, plant and equipment, net$0.00$10.4M$16.1M$34.4M$40.6M
Goodwill and intangible assets$59M$59M$95.1M$131.1M$167.2M
Long-term investments$0.00$0.00$0.00$0.00$0.00
Total non-current assets$191.7M$106.8M$123.6M$170.9M$258.2M
Total assets$376.6M$220.7M$241.7M$356.1M$529.4M
Accounts payable$21.2M$15.2M$14.6M$18M$33.6M
Short-term debt$40.1M$9.71M$24M$36.7M$102.3M
Deferred revenue$0.00$0.00$0.00$3.74M$20.9M
Total current liabilities$162.9M$80.9M$99.9M$129.5M$261.1M
Long-term debt$176.2M$179M$80.1M$63M$86.8M
Deferred revenue, non-current$0.00$0.00$43.3M$43.3M$21.5M
Total non-current liabilities$181M$188.9M$172.4M$221.3M$194.3M
Capital lease obligations$0.00$8.95M$13.4M$33.7M$38.5M
Total liabilities$344M$269.9M$272.3M$350.8M$455.3M
Common stock$0.00$0.00$0.00$0.00$0.00
Retained earnings-$-1.68B-$-1.68B-$-1.61B-$-1.56B-$-1.46B
Accumulated other comprehensive income (loss)$10K$10K$10K$10K$10K
Total equity$32.6M-$-49.19M-$-30.58M$5.23M$74M
Total investments$0.00$0.00$0.00$0.00$0.00
Total debt$216.3M$188.7M$104.2M$99.8M$189.1M
Net debt$31.5M$136.9M$61.3M$9.32M$39.3M
Cash flow statement
20252024202320222021
Net income-$-5.34M-$-69.41M-$-51.92M-$-92.56M-$-282.02M
Depreciation and amortization$1.27M$37.5M$41.9M$37.7M$36.1M
Stock-based compensation$11.3M$7.78M$9.32M$17.9M$22.7M
Change in working capital$16.5M-$-39.68M-$-20.73M-$-1.44M-$-105.61M
Accounts receivable-$-14.14M$4.05M$990K$11.7M-$-24.03M
Inventory-$-23.12M-$-28.4M-$-2.54M$19.8M-$-24.95M
Accounts payable$3.08M-$-1.36M-$-5.24M$1.5M-$-11.73M
Net cash provided by operating activities$68M-$-40.66M-$-23.38M-$-73.15M-$-252.97M
Investments in property, plant and equipment$0.00-$-30K$0.00-$-110K-$-60K
Acquisitions, net$0.00$0.00$0.00$0.00$0.00
Net cash used for investing activities-$-7.93M-$-30K$0.00-$-110K$39.9M
Common stock issued$68.4M$42.7M$6.79M$7.53M$89M
Common stock repurchased$0.00-$-1.27M$0.00$0.00$0.00
Dividends paid$0.00$0.00$0.00$0.00$0.00
Net cash used for financing activities$72.9M$49.7M-$-25.21M$14.6M$133.7M
Net change in cash$133M$8.97M-$-48.59M-$-58.67M-$-79.29M
Cash at end of period$186.5M$53.6M$44.6M$93.2M$149.8M
Operating cash flow$68M-$-40.66M-$-23.38M-$-73.15M-$-252.97M
Capital expenditure-$-290K-$-30K$0.00-$-110K-$-60K
Free cash flow$68M-$-40.69M-$-23.38M-$-73.27M-$-253.02M
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About Akebia Therapeutics, Inc.

        Akebia Therapeutics, Inc., established in 2007 and headquartered in Cambridge, Massachusetts, is a biopharmaceutical company focused on discovering and commercializing therapies for patients suffering from kidney diseases. The firm's leading experimental drug, vadadustat, is an oral treatment currently in Phase III clinical trials. Its purpose is to address anemia resulting from chronic kidney disease (CKD) in adult patients, encompassing both those dependent on dialysis and those who are not. Akebia also markets Auryxia, a ferric citrate product used to manage serum phosphorus levels in adult CKD patients undergoing dialysis, and to treat iron deficiency anemia in adult CKD patients who are not on dialysis. The company has several key collaboration agreements: with Otsuka Pharmaceutical Co. Ltd. for vadadustat's development and commercialization across major regions including the United States, European Union, Russia, China, Australia, Canada, and the Middle East; with Mitsubishi Tanabe Pharma Corporation for vadadustat in Japan and other Asian territories; and a research and licensing deal with Janssen Pharmaceutica NV pertaining to hypoxia-inducible factor prolyl hydroxylase targeted compounds globally.

        CEO
        John Butler
        Employees
        194
        Beta
        0.23

        Explore

        Frequently asked questions

        What is the intrinsic value of Akebia Therapeutics, Inc. (AKBA)?

        InvestorsCraft does not currently publish an intrinsic value for AKBA. How the IC value is calculated.

        Is AKBA undervalued?

        InvestorsCraft does not publish an undervaluation signal for AKBA at this time.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.